What happens if chemotherapy stops working for DLBCL that transformed from follicular lymphoma?

When standard chemotherapy lines fail, CAR-T cell therapy is often the next option for eligible patients, including those with refractory or relapsed disease. ChinaCureLink can help arrange a case review to determine whether CAR-T therapy may be appropriate.

What are the risks of CAR-T cell therapy, and how are complications managed?

CAR-T therapy can cause serious side effects, including complications requiring intensive care, as seen in this case. Hospitals experienced in CAR-T treatment have dedicated protocols and ICU-level support to manage these complications closely during the post-infusion period.

How can international patients access CAR-T therapy for relapsed or refractory DLBCL in China?

Access typically starts with a case review, where medical records, pathology, and treatment history are submitted for evaluation. ChinaCureLink coordinates this process and helps match patients with hospitals experienced in CAR-T cell therapy for their specific diagnosis.

top of page

FREE CONSULTATION

ChinaCurelink
a MedeboundHEALTH Company

Relapsed DLBCL to Complete Remission: A CAR-T Cell Therapy Case Study in China

ChinaCureLink

Mon Aug 31 2026

6 min read

Widget Didn’t Load

Check your internet and refresh this page.

If that doesn’t work, contact us.

bottom of page